Related Experiment Videos
[Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation]
Revue Neurologique
|March 23, 2004
Summary
Congenital Myasthenic Syndromes (CMS) are genetic disorders affecting neuromuscular transmission. Advances in genetic analysis have identified various CMS types, aiding diagnosis and targeted therapies for improved patient outcomes.
Area of Science:
- Neurology
- Genetics
- Molecular Biology
Context:
- Congenital Myasthenic Syndromes (CMS) represent a diverse group of inherited neuromuscular junction disorders.
- Recent decades have seen significant progress in understanding the genetic underpinnings of CMS, identifying defects in presynaptic, synaptic, and postsynaptic proteins.
Purpose:
- To outline the diagnostic criteria and pathophysiological characterization of various CMS types.
- To highlight the genetic basis of CMS, including mutations in acetylcholine receptor (AChR) subunits, rapsyn, SCN4A sodium channels, and acetylcholinesterase (AChE).
Summary:
- CMS diagnosis involves clinical signs, response to medications, family history, and specific electrophysiological and genetic tests.
- Postsynaptic CMS, often due to AChR subunit mutations, can manifest as Slow Channel Syndrome or AChR deficiency. Synaptic CMS involves AChE deficiency, while presynaptic CMS is frequently linked to choline acetyltransferase defects.
- Uncharacterized CMS cases may require advanced investigations like linkage analysis and microelectrophysiological studies.
Impact:
- Accurate diagnosis and pathophysiological characterization enable genetic counseling and tailored therapeutic strategies.
- Treatment options include anticholinesterase medications, 3,4-diaminopyridine (3,4-DAP), and specific drugs like quinidine and fluoxetine for Slow Channel Syndrome.
- Full characterization of CMS cases leads to improved patient management and potential for novel therapeutic development.